Wellion Calla Light
The technology used in the Wellion Calla Light, to measure blood glucose, has passed in a clinical validation study, in a general population, according to a recognised standard protocol, as published in a peer-reviewed publication.
|Medaval||★ Recommendation||Recent clinical validation; older protocol|
Freckmann G, Schmid C, Baumstark A, Pleus S, Link M, Haug C. System accuracy evaluation of 43 blood glucose monitoring systems for self-monitoring of blood glucose according to DIN EN ISO 15197. J Diabetes Sci Technol. 2012 Sep 1;6(5):1060-75. PMID: 23063032. Available from: PMC3570840.
15197:2003 - Fail General population
15197:2013 - Fail General population
Chlup R, Doubravova B, Bartek J, Zapletalova J, Krystynik O, Prochazka V. Effective assessment of diabetes control using personal glucometers (CONTOURLINK, Bayer, Germany; CALLA, Wellion, Austria; LINUS, Agamatrix, USA). Dis Markers. 2013;35(6):895-905. PMID: 24427777.
Ad Hoc protocol General population
While ISO 15197:2003 and ISO 15197:2013 are mentioned, it is unclear if either was folowed.
SKUP. Report from the evaluation SKUP/2013/87: Wellion Calla Light (MED TRUST Handelsgesellschaft), a system for blood glucose measurement. Uppsala, Sweden: SKUP; 2013. 59 p. Available from: skup.org.
15197:2003 General population (Note: BLS-recorded measurements)
15197:2003 - Pass General population (Note: Subject-recorded measurements)